Abstract

Adaptimmune designs, develops, and delivers T-cell therapies for solid tumors. By engineering T-cell receptors (TCRs) to a high affinity against cancer antigens, the Company has built a broad pipeline to target solid tumors. As an integrated cell therapy company, Adaptimmune uses in-house manufacturing capabilities to introduce its proprietary engineered TCRs into patient’s own T-cells, thus empowering a person’s own immune system to fight their disease. With added next-generation enhancements to improve efficacy, and a rapidly developing allogeneic program to provide off-the-shelf T-cell therapies to any eligible patient, Adaptimmune is at the forefront of immuno-oncology.